Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

• Mark M. Awad,
• Yvan Le Bruchec,
• Brian Lu,
• Jason Ye,
• Julie Ann Miller,
• Patrick H. Lizotte,
• Megan E. Cavanaugh,
• Amanda J. Rode,
• Calin Dan Dumitru,
• Alexander Spira

Affiliations

Mark M. Awad

Lowe Center for Thoracic Oncology and Dana-Farber Cancer Institute, Boston, MA, United States

Yvan Le Bruchec

Bristol Myers Squibb, Princeton, NJ, United States

Brian Lu

Bristol Myers Squibb, Princeton, NJ, United States

Jason Ye

Acetylon Pharmaceuticals, Inc, Boston, MA, United States

Julie Ann Miller

Bristol Myers Squibb, Princeton, NJ, United States

Patrick H. Lizotte

Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States

Megan E. Cavanaugh

Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States

Amanda J. Rode

Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States

Calin Dan Dumitru

Bristol Myers Squibb, Princeton, NJ, United States

Alexander Spira

Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA, United States